CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Tirzepatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03940742
NCT03940742Phase 1Completed
CompareCT.gov

A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment

Eli Lilly and Company·interventional·Posted May 7, 2019·Updated Mar 24, 2023

In Brief

A Phase 1 clinical trial evaluating Tirzepatide for Hepatic Insufficiency. Completed, enrolled 32 participants across 3 sites.

Detailed Summary

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Insufficiency
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedMay 7, 2019
Enrollment StartJul 22, 2019
Primary CompletionSep 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.2 years ago

Interventions

Tirzepatidedrug

Administered SC